Study on the Therapeutic Effect and Regulatory Mechanism of Bevacizumab Combined with Chemotherapy in Epithelial Ovarian Cancer Based on NF-κB/HIF-1α/VEGF Signal Pathway
Objective To explore the clinical efficacy of bevacizumab combined with chemotherapy in the treatment of ovarian cancer and its possible mechanisms,so as to provide reference for the development of new ovarian cancer therapy.Meth-ods SKOV3 cells were treated with bevacizumab and chemotherapy drugs,then the apoptosis,growth and invasion abilities of SKOV3 cells were measured by flow cytometry,colony-forming assay and Transwell chamber assay,respectively.Meantime,SK-OV3 cells were injected subcutaneously into BALBc-Nude nude mice to induce tumor models,and the therapeutic effects of bev-acizumab combined with chemotherapy drugs were evaluated through measuring the tumor volume and size.The Ki-67 expression was detected by immunohistochemistry.The expression of NF-κB/HIF-1α/VEGF as well as Bax and Bcl-2 proteins was detected by Western blotting.Results In vitro studies revealed that bevacizumab combined with chemotherapy could inhibit the expression of NF-κB/HIF-1α/VEGF signaling pathway related proteins in SKOV3 cells,inhibit the proliferation and invasion ability of SK-OV3 cells and promote apoptosis of SKOV3 cells.In vivo studies demonstrated that bevacizumab combined with chemotherapy could inhibit the expression of NF-κB/HIF-1α/VEGF signaling pathway related proteins in tumor tissues,as well as inhibit tumor growth and suppress Ki-67 protein expression in tumor tissues.Conclusion Bevacizumab combined with chemotherapy regimens can effectively restrain the malignant progression of ovarian cancer,and this effect may be associated with inhibition of the NF-κB/HIF-1α/VEGF signaling pathway.
万方数据
维普
